Apogee Therapeutics (APGE) Cash & Equivalents (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Cash & Equivalents data on file, last reported at $451.8 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 322.57% year-over-year to $451.8 million in Q1 2026; TTM through Mar 2026 was $451.8 million, a 322.57% increase from a year earlier, with the FY2025 full-year figure at $131.5 million, down 7.22% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $451.8 million, up from $131.5 million in the prior quarter.
• Over the last five years, Cash & Equivalents for APGE reached as high as $485.5 million in Q1 2024 and fell as low as $5.0 million in Q2 2022.
• Historically, Cash & Equivalents has averaged $183.2 million across 5 years, with a median of $128.3 million in 2023.
• Across the five-year window, Cash & Equivalents surged 2414.46% in 2023 and plunged 77.98% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $151.9 million in 2022, then retreated by 22.1% to $118.3 million in 2023, then grew by 19.84% to $141.8 million in 2024, then dropped by 7.22% to $131.5 million in 2025, then soared by 243.44% to $451.8 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $451.8 million in Q1 2026, $131.5 million in Q4 2025, and $107.9 million in Q3 2025.